Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HA 0.15% vs Cyclosporine 0.05% in Dry Eye Disease
NCT04127851Phase 4Completed
- Sponsor
- Taejoon Pharmaceutical Co., Ltd.
- Start
- Nov 2019
- Primary completion
- Jul 2021
- Modality
- Polymer-based Nanoparticles
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of Aili in dry eye syndrome (DED) (3 arms), sponsored by Taejoon Pharmaceutical Co., Ltd. Primary endpoint: Change From Baseline in Corneal Staining Score at 12 weeks. Started Nov 2019; status: completed.
02
Drugs
Aili
03
Conditions
dry eye syndrome (DED)
Beyond the preview
Go deeper on NCT04127851.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04127851.